At Ferring, we are transforming the potential of microbiome restoration into novel live biotherapeutics. Harnessing that power requires the kind of inquisitive minds, innovative problem solving, rigorous scientific standards, and leadership that have been the foundation of Ferring for 70 years. As a private company, we have the freedom to focus on what matters most—delivering treatments that improve the lives of patients and allowing us the courage to invest in areas others won’t.

The microbiome is a highly-diverse microbial community that plays an essential role in our health. There’s a growing body of evidence that shows when there is a disruption of the composition and/or diversity of the gut microbiome, there may be an associated risk for serious illnesses. Now Ferring is shedding light on the link between disease and disruptions in the gut microbiome, exploring the potential for repopulating its diversity and restoring hope to patients.

Ferring aims to deliver innovative therapeutics to help people live better lives. This principle guides our current work pioneering an entirely new category and developing scientifically validated, microbiome-based therapeutics that are standardized for quality and safety. We start with the end in mind—breaking the unrelenting cycle of recurrent C. difficile infection.

Ferring has embarked on a bold new course, pioneering a category of microbiome-based therapeutics to help people live better lives and advance current standards of care. While we are starting with recurrent C. difficile infection, we believe this is only the beginning of how we harness the power of the microbiome to fight disease.